Medical treatment of prolactinomas

Nature Reviews Endocrinology

Volumn 7, Issue 5, 2011, Pages 267-278

  Colao, Annamaria ^a   Savastano, Silvia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BIM 23A387; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; ERGOTAMINE; FENFLURAMINE; FULVESTRANT; GANCICLOVIR; LISURIDE MALEATE; METERGOLINE; METHYSERGIDE; NUCLEOSIDE DERIVATIVE; OCTREOTIDE; PASIREOTIDE; PERGOLIDE; PROLACTIN; QUINAGOLIDE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; TAMOXIFEN; TEMOZOLOMIDE; TERGURIDE; TESTOSTERONE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

CALCIFICATION; CANCER RADIOTHERAPY; DISEASE ASSOCIATION; DISEASE CONTROL; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; GENE THERAPY; HEART VALVE REGURGITATION; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; MORBIDITY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; REMISSION; REVIEW; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE; VOMITING;

DOPAMINE AGONISTS; HUMANS; HYPOGONADISM; PROLACTIN; PROLACTINOMA;

EID: 79955094437     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2011.37     Document Type: Review

References (134)

1. Colao, A. & Lombardi, G. Growth-hormone and prolactin excess. Lancet 352, 1455-1461 (1998). (Pubitemid 28510890)
2. Ciccarelli, A., Daly, A. F. & Beckers, A. The epidemiology of prolactinomas. Pituitary 8,3-6 (2005). (Pubitemid 44680079)
3. Colao, A. et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325-331 (2003). (Pubitemid 36410718)
4. Mindermann, T. & Wilson, C. B. Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. (Oxf.) 41, 359-364 (1994). (Pubitemid 24278331)
5. Colao, A. M. Pituitary adenomas in childhood [online], http://www.endotext.org/pediatrics/pediatrics3/pediatricsframe3.htm (2006).
6. Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485-534 (2006). (Pubitemid 44213229)
7. Colao, A. Pituitary tumours: the prolactinoma. Best Pract. Res. Clin. Endocrinol. Metab. 23, 575-596 (2009).
8. George, L. D., Nicolau, N., Scanlon, M. F. & Davies, J. S. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin. Endocrinol. (Oxf.) 53, 595-599 (2000).
9. Bevan, J. S., Webster, J., Burke, C. W. & Scanlon, M. F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13, 220-240 (1992).
10. Colao, A., Annunziato, L. & Lombardi, G. Treatment of prolactinomas. Ann. Med. 30, 452-459 (1998). (Pubitemid 28479491)
11. Colao, A., di Sarno, A., Pivonello, R., di Somma, C. & Lombardi, G. Dopamine receptor agonists for treating prolactinomas. Expert Opin. Investig. Drugs 11, 787-800 (2002). (Pubitemid 34618811)
12. Vilar, L. et al. Management of prolactinomas in Brazil: an electronic survey. Pituitary 13, 199-206 (2010).
13. Klibanski, A. & Greenspan, S. L. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 315, 542-546 (1986). (Pubitemid 16014768)
14. Colao, A. et al. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Horm. Res. 44, 222-228 (1995).
15. Di Somma, C. et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J. Clin. Endocrinol. Metab. 83, 807-813 (1998). (Pubitemid 28496451)
16. Sabuncu, T., Arikan, E.,Tasan, E. & Hatemi, H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern. Med. 40, 857-861 (2001). (Pubitemid 32958781)
17. Di Sarno, A. et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J. Clin. Endocrinol. Metab. 86, 5256-5261 (2001).
18. Passos, V. Q.,Souza, J. J., Musolino, N. R. & Bronstein, M. D. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J. Clin. Endocrinol. Metab. 87, 3578-3582 (2002). (Pubitemid 34879499)
19. Chattopadhyay, A., Bhansali, A. & Masoodi, S. R. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 8,147-154 (2005).
20. De Rosa, M. et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur. J. Endocrinol. 138, 286-293 (1998). (Pubitemid 28154778)
21. Schettini, G. et al. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin. Endocrinol. (Oxf.) 33, 161-169 (1990). (Pubitemid 20233591)
22. Beckers, A. et al. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. J. Clin. Endocrinol. Metab. 75, 275-280 (1992).
23. Colao, A., Lombardi, G. & Annunziato, L. Cabergoline. Expert Opin. Pharmacother. 1, 555-574 (2000).
24. Webster, J. et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331, 904-909 (1994). (Pubitemid 24299871)
25. Verhelst, J. et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518-2522 (1999).
26. Di Sarno, A. et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin. Endocrinol. (Oxf.) 53, 53-60 (2000). (Pubitemid 30646126)
27. Biller, B. M. et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81, 2338-2343 (1996). (Pubitemid 26175965)
28. Colao, A. et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J. Clin. Endocrinol. Metab. 82, 3574-3579 (1997). (Pubitemid 27509339)
29. Colao, A. et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J. Clin. Endocrinol. Metab. 85, 2247-2252 (2000). (Pubitemid 32269250)
30. De Rosa, M. et al. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine 20, 75-82 (2003). (Pubitemid 36515190)
31. Colao, A. et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704-1711 (2004). (Pubitemid 38507923)
32. De Rosa, M. et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J. Clin. Endocrinol. Metab. 89, 621-625 (2004). (Pubitemid 38269868)
33. Colao, A. et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 82, 876-883 (1997). (Pubitemid 27106605)
34. Delgrange, E., Duprez, T. & Maiter, D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin. Endocrinol. (Oxf.) 64, 456-462 (2006).
35. Ono, M. et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721-4727 (2008).
36. Delgrange, E., Daems., T., Verhelst, J., Abs, R. & Maiter, D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur. J. Endocrinol. 160, 747-752 (2009).
37. Barlier, A. & Jaquet, P. Quinagolide - a valuable treatment option for hyperprolactinaemia. Eur. J. Endocrinol. 154, 187-195 (2006).
38. Colao, A. et al. Chronic treatment with CV 205-502 restores the gonadal function in hyperprolactinemic males. Eur. J. Endocrinol. 135, 548-552 (1996). (Pubitemid 26396278)
39. Vance, M. L. et al. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205-502. Ann. Intern. Med. 112, 668-673 (1990). (Pubitemid 20137175)
40. Homburg, R., West, C., Brownell, J. & Jacobs, H. S. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205-502, with bromocriptine in women with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 32, 565-571 (1990). (Pubitemid 20151452)
41. De Luis, D. A. et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J. Endocrinol. Invest. 23, 428-434 (2000).
42. Giusti, M. et al. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. J. Endocrinol. Invest. 17, 51-57 (1994). (Pubitemid 24162544)
43. Andersohn, F. & Garbe, E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov. Disord. 24, 129-133 (2009).
44. Freda, P. U. et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J. Clin. Endocrinol. Metab. 85, 8-13 (2000). (Pubitemid 32268782)
45. Orrego, J. J., Chandler, W. F. & Barkan, A. L. Pergolide as primary therapy for macroprolactinomas. Pituitary 3, 251-256 (2000). (Pubitemid 34026501)
46. Gräf, K. J., Neumann, F. & Horowski, R. Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology 98, 598-605 (1976).
47. Liuzzi, A. et al. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans. J. Clin. Endocrinol. Metab. 46, 196-202 (1978). (Pubitemid 8312319)
48. Dallabonzana, D. et al. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J. Clin. Endocrinol. Metab. 63, 1002-1007 (1986). (Pubitemid 16004309)
49. Schade, R., Andersohn, F.,Suissa,S., Haverkamp, W. & Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356, 29-38 (2007). (Pubitemid 46041751)
50. Zanettini, R. et al. Valve heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39-46 (2007). (Pubitemid 46041752)
51. Rothman, R. B. et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836-2841 (2000).
52. Singh, J. P. et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am. J. Cardiol. 83, 897-902 (1999). (Pubitemid 29143128)
53. Choong, C.Y. et al. Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am. Heart J. 117, 636-642 (1989). (Pubitemid 19078162)
54. Kars, M., Pereira, A. M., Bax, J. J. & Romijn, J. A. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur. J. Endocrinol. 159, 363-367 (2008).
55. Colao, A. et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab. 93, 3777-3784 (2008).
56. Bogazzi, F. et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int. J. Clin. Pract. 62, 1864-1869 (2008).
57. Bogazzi, F. et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J. Endocrinol. Invest. 31, 1119-1123 (2008).
58. Cheung, D. & Heaney, A. Dopamine agonists and valvular heart disease. Curr. Opin. Endocrinol. Diabetes Obes. 16, 316-320 (2009).
59. Valassi, E., Klibanski, A. & Biller, B. M. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J. Clin. Endocrinol. Metab. 95, 1025-1033 (2010).
60. Tan, L. C. et al. Bromocriptine use and the risk of valvular heart disease. Mov. Disord. 24, 344-349 (2009).
61. Steiger, M., Jost, W., Grandas, F. & Van Camp, G. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J. Neural Transm. 116, 179-191 (2009).
62. Zanettini, R. et al. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc. Ther. doi:10.1111/ j.1755-5922.2010.00169.x.
63. Rasmussen, V. G. et al. Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study. J. Heart Valve Dis. 18, 463-469 (2009).
64. Gu, H., Luck, S., Carroll, P. V., Powrie, J. & Chambers, J. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clin. Endocrinol. (Oxf.) doi:10.1111/j.1365-2265.2010.03973.x.
65. Johnston, D. G. et al. Hyperprolactinemia. Long-term effects of bromocriptine. Am. J. Med. 75, 868-874 (1983). (Pubitemid 13023296)
66. Zarate, A., Canales, E. S., Cano, C. & Pilonieta, C. J. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol. (Copenh.) 104, 139-142 (1983). (Pubitemid 13000587)
67. Moriondo, P., Travaglini, P., Nissim, M., Conti, A. & Faglia, G. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J. Clin. Endocrinol. Metab. 60, 764-772 (1985). (Pubitemid 15147568)
68. Johnston, D. G. et al. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet 2, 187-192 (1984). (Pubitemid 14094955)
69. Maxson, W. S., Dudzinski, M., Handwerger, S. H. & Hammond, C. B. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil. Steril. 41, 218-223 (1984). (Pubitemid 14169506)
70. Wang, C. et al. Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin. Endocrinol. (Oxf.) 27, 363-371 (1987). (Pubitemid 17138340)
71. Winkelmann, W., Allolio, B., Deuss, U., Heesen, D. & Kaulen, D. in Prolactin. Basic and Clinical Correlates (eds MacLeod, R. M., Thorner, M. O. & Scapagnini, U.) 817-822 (Liviana Press, Padova, 1985).
72. Rasmussen, C., Brownell, J. & Bergh, T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinol. (Copenh.) 125, 170-176 (1991).
73. van't Verlaat, J. W. & Croughs, R. J. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin. Endocrinol. (Oxf.) 34, 175-178 (1991).
74. Ferrari, C. et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 126, 489-494 (1992).
75. Muratori, M. et al. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest. 20, 537-546 (1997). (Pubitemid 28014506)
76. Cannavò, S. et al. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. Endocrinol. Invest. 22, 354-359 (1999). (Pubitemid 29259557)
77. Colao, A. et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349, 2023-2033 (2003). (Pubitemid 37448925)
78. Biswas, M. et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin. Endocrinol. (Oxf.) 63, 26-31 (2005). (Pubitemid 40966398)
79. Kharlip, J., Salvatori, R., Yenokyan, G. & Wand, G. S. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94, 2428-2436 (2009).
80. Colao, A. et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin. Endocrinol. (Oxf.) 67, 426-433 (2007). (Pubitemid 47283843)
81. Huda, M.S., Athauda, N. B., Teh, M.M., Carroll, P.V. & Powrie, J. K. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin. Endocrinol. (Oxf.) 72, 507-511 (2010).
82. Crosignani, P.G. et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur. J. Obstet Gynecol. Reprod. Biol. 44, 175-180 (1992).
83. Karunakaran, S., Page, R. C. & Wass, J. A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 54, 295-300 (2001). (Pubitemid 32234192)
84. Koppelman, M. C., Jaffe, M. J., Rieth, K. G., Caruso, R. C. & Louriaux, D. L. Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Ann. Intern. Med. 100, 115-121 (1984). (Pubitemid 14219140)
85. Jeffcoate, W. J., Pound, N., Sturrock, N. D. & Lambourne, J. Long-term follow-up of patients with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 45, 299-303 (1996). (Pubitemid 26306698)
86. Schlechte, J., Dolan, K., Sherman, B., Chapler, F. & Luciano, A. The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412-418 (1989). (Pubitemid 19052886)
87. Sisam, D. A.,Sheehan, J. P. & Sheeler, L. R. The natural history of untreated microprolactinomas. Fertil. Steril. 48, 67-71 (1987). (Pubitemid 17093255)
88. Dekkers, O. M. et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95, 43-51 (2010).
89. Casanueva, F. F. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 65, 265-273 (2006). (Pubitemid 44079693)
90. Kaltsas, G. A., Nomikos, P., Kontogeorgos, G., Buchfelder, M. & Grossman, A. B. Clinical review: Diagnosis and management of pituitary carcinomas. J. Clin. Endocrinol. Metab. 90, 3089-3099 (2005). (Pubitemid 40686369)
91. Colao, A. et al. Pituitary carcinomas. Front. Horm. Res. 38, 94-108 (2010).
92. Zada, G. et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J. Neurosurg. 114, 336-344 (2011).
93. Fainstein Day, P. et al. Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue. Front Horm. Res. 38, 50-58 (2010).
94. Shimon, I., Benbassat, C. & Hadani, M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur. J. Endocrinol. 156, 225-231 (2007). (Pubitemid 46554517)
95. Thapar, K. et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38, 99-106 (1996).
96. Thapar, K., Scheithauer, B. W., Kovacs, K., Pernicone, P. J. & Laws, E. R. Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38, 765-770 (1996).
97. Turner, H. E., Harris, A. L., Melmed, S. & Wass, J. A. Angiogenesis in endocrine tumors. Endocr. Rev. 24, 600-632 (2003). (Pubitemid 37330584)
98. Molitch, M. E. Dopamine resistance of prolactinomas. Pituitary 6, 19-27 (2003). (Pubitemid 37455641)
99. Delgrange, E., Crabbé, J. & Donckier, J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm. Res. 49, 250-253 (1998). (Pubitemid 28165744)
100. McCall, D. et al. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clin. Endocrinol. (Oxf.) 66, 149-150 (2007). (Pubitemid 44952509)
101. Behan, L. A. et al. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary doi:10.1007/s11102-009-0168-0.
102. Lania, A. G. et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J. Clin. Endocrinol. Metab. 95, 13-17 (2010).
103. Gillam, M. P., Middler, S., Freed, D. J. & Molitch, M. E. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J. Clin. Endocrinol. Metab. 87, 4447-4451 (2002). (Pubitemid 35247022)
104. Colao, A., Faggiano, A. & Pivonello, R. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. Prog. Brain Res. 182, 281-294 (2010).
105. Shimon, I. et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J. Clin. Invest. 100, 2386-2392 (1997). (Pubitemid 27500164)
106. Bronstein, M. D. et al. Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia. Norm. Metab. Res. 19, 271-274 (1987). (Pubitemid 17082615)
107. Lamberts, S. W. et al. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201-995 in patients with prolactinomas and acromegaly. Clin. Endocrinol. (Oxf.) 25, 201-212 (1986). (Pubitemid 16046359)
108. Greenman, Y. & Melmed, S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 79, 724-729 (1994). (Pubitemid 24286392)
109. Hofland, L. J. & Lamberts, S. W. J. in Molecular Pathology of the Pituitary (eds Kontogeorgos, G. & Kovacs, K.) 235-252 (Karger, Basel, 2004).
110. Rocheville, M. et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154-157 (2000). (Pubitemid 30203051)
111. Ren, S.G. et al., Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J. Clin. Endocrinol. Metab. 88, 5414-5421 (2003).
112. Saveanu, A. et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. 87, 5545-5552 (2002). (Pubitemid 36034358)
113. Gorski, J., Wendell, D., Gregg, D. & Chun, T. Y. Estrogens and the genetic control of tumor growth. Prog. Clin. Biol. Res. 396, 233-243 (1997).
114. Heaney, A. P., Fernando, M. & Melmed, S. Functional role of estrogen in pituitary tumor pathogenesis. J. Clin. Invest. 109, 277-283 (2002). (Pubitemid 34083748)
115. Lamberts, S. W., Verleun, T. & Oosterom, R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 34, 339-342 (1982). (Pubitemid 12142645)
116. Goffin, V., Bernichtein, S., Touraine, P. & Kelly, P.A. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 26, 400-422 (2005). (Pubitemid 40686651)
117. Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350-1354 (2000).
118. Ekeblad, S. et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 13, 2986-2991 (2007). (Pubitemid 46849574)
119. Raverot, G. et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J. Clin. Endocrinol. Metab. 95, 4592-4599 (2010).
120. McCormack, A. I. et al. Low 06-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin. Endocrinol. (Oxf.) 71, 226-233 (2009).
121. Mohammed, S., Kovacs, K., Mason, W., Smyth, H. & Cusimano, M. D. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64, E773-E774; discussion E774 2009.
122. Thearle, M. et al. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor. Pituitary doi:10.1007/s11102-009-0211-1.
123. Wilson, J. M. Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 334, 1185-1187 (1996).
124. Lee, E. J. & Jameson, J. L. Gene therapy of pituitary diseases. J. Endocrinol. 185, 353-362 (2005). (Pubitemid 40883380)
125. Williams, J. C. et al. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Mol. Ther. 4, 593-602 (2001). (Pubitemid 34026875)
126. Vallette, S. et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12, 153-157 (2009).
127. rd & Blevins, L. S. Jr. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr. Pract. 14, 672-677 (2008).
128. Lancellotti, P. et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur. J. Endocrinol. 159, 1-5 (2008). (Pubitemid 351969123)
129. Kars, M. et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. 93, 3348-3356 (2008).
130. Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka-Bennett, A. & Atkin, S. L. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur. J. Endocrinol. 159, R11-R14 (2008).
131. Herring, N., Szmigielski, C., Becher, H., Karavitaki, N. & Wass, J. A. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol. (Oxf.) 70, 104-108 (2009).
132. Nachtigall, L. B. et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin. Endocrinol. (Oxf.) 72, 53-58 (2010).
133. Lafeber, M. et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur. J. Endocrinol. 162, 667-675 (2010).
134. Tan, T. et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 73, 369-374 (2010).